Quick answer: Reshma Shetty is a co-founder of Ginkgo Bioworks, a synthetic biology company she helped launch in 2008 alongside Jason Kelly, Austin Che, Barry Canton, and Tom Knight. Trained as a biological engineer at MIT, Shetty has become one of the most recognized women in biotech entrepreneurship, helping build Ginkgo into a publicly traded company that engineers organisms for industries ranging from agriculture to pharmaceuticals.
Few founder stories capture the intersection of academic research and entrepreneurial risk-taking quite like Reshma Shetty’s. While most biotech leaders come from either the lab or the boardroom, Shetty built her career by refusing to choose between the two. Her path from MIT’s synthetic biology labs to co-founding one of the industry’s most talked-about companies offers a blueprint for scientists who want to build something bigger than a research paper.
This piece looks at who Reshma Shetty is, how Ginkgo Bioworks came to be, and why her story matters for a new generation of women eyeing careers in biotech entrepreneurship.
Table of Contents
Who Is Reshma Shetty and How Did Her Career in Biotech Begin?
Reshma Shetty earned her Ph.D. in biological engineering from the Massachusetts Institute of Technology, where she studied under synthetic biology pioneer Tom Knight. It was during her time at MIT that Shetty began working alongside a small group of researchers who shared a common frustration: engineering biology was still far too slow, expensive, and unpredictable compared to other engineering disciplines like electronics or software.
That frustration became the seed of Ginkgo Bioworks. Shetty, along with Knight and fellow MIT researchers Jason Kelly, Austin Che, and Barry Canton, set out to change how organisms are engineered — treating biology less like an unpredictable science experiment and more like a repeatable, scalable engineering process.
What Is Ginkgo Bioworks and Why Did Reshma Shetty Help Start It?
Ginkgo Bioworks was founded in 2008 with a clear mission: make it easier, faster, and cheaper to program cells the way software engineers program computers. Instead of manually designing organisms one at a time, Ginkgo built automated platforms that could design, build, and test thousands of genetic combinations in parallel.
Reshma Shetty took on the role of scaling this vision into a functioning business. Her work focused heavily on translating dense scientific research into commercial applications that industries could actually use — from creating custom microbes for agriculture to supporting pharmaceutical development.
Choose synthetic biology platforms like Ginkgo’s if your industry needs custom-engineered organisms at scale rather than one-off lab solutions. This distinction — mass biological engineering versus boutique lab work — is central to understanding why Ginkgo Bioworks stood out in a crowded biotech field.
By 2021, Ginkgo Bioworks went public through a SPAC merger, a milestone that placed the company — and its founding team — firmly in the spotlight of the biotech industry.
Why Does Reshma Shetty’s Story Matter for Women in Biotech Entrepreneurship?
Women remain significantly underrepresented in biotech leadership, particularly in synthetic biology and deep-tech startups. Reshma Shetty’s visibility as a co-founder of a publicly traded biotech company offers a counterpoint to that trend.
Her story matters for a specific reason: she didn’t step into an existing company as a hire. She helped build the company from its earliest scientific concept, straight through to a public listing. That kind of full-cycle founder experience — research, prototype, scale, IPO — is rare, and even rarer among women in the biotech sector.
For young female scientists considering the leap from academia to entrepreneurship, Shetty’s career illustrates a realistic path: deep technical expertise combined with a willingness to commercialize that expertise, rather than keep it confined to a lab.
What Can Aspiring Biotech Founders Learn From Reshma Shetty’s Approach?
A few patterns stand out when looking at how Reshma Shetty and her co-founders approached building Ginkgo Bioworks:
- Start with a technical bottleneck, not just an idea. Ginkgo Bioworks was founded to solve a specific engineering problem — the slow, manual process of designing organisms — rather than chasing a trend.
- Build a founding team with complementary technical depth. Shetty co-founded the company with peers from the same MIT lab, ensuring the founding team shared both technical fluency and a common research foundation.
- Focus on infrastructure, not just one product. Rather than building a single biotech product, Ginkgo built a platform that other companies could use to create their own biological products, positioning it as foundational infrastructure for the industry.
- Be prepared for a long runway. Ginkgo Bioworks operated for over a decade before going public, reflecting the extended timelines common in biotech compared to software startups.
These principles apply broadly to founders working in deep-tech fields, where scientific validation often takes years longer than in consumer technology.
Founder Stories Worth Following in Biotech and Beyond
Reshma Shetty’s path from MIT researcher to biotech company builder sits alongside a broader pattern of technical founders who transitioned from research environments into public companies. For readers interested in similar journeys, founderstories.net’s profile on Diane Greene explores how another technical leader built VMware from an engineering-first foundation into an industry-defining company. Readers curious about how enterprise-focused founders scale platform businesses may also find the story of Glean co-founder Arvind Jain a useful comparison point.
For deeper background on Ginkgo Bioworks’ current work in synthetic biology, the company’s own site at ginkgobioworks.com offers additional detail on its platform and ongoing projects.
The Bigger Picture: Why Founder Stories Like Reshma Shetty’s Deserve More Attention
Biotech entrepreneurship rarely gets the same cultural spotlight as software startups, despite the outsized impact it has on agriculture, medicine, and manufacturing. Reshma Shetty’s role in building Ginkgo Bioworks deserves recognition not just as a biotech milestone, but as a rare example of a woman leading a scientific company from its earliest research stage through to public markets.
As more industries lean on engineered biology — from sustainable materials to personalized medicine — founders with Shetty’s background will likely become more common. Her story serves as an early marker of what that future may look like.
Frequently Asked Questions
Who is Reshma Shetty?
Reshma Shetty is a co-founder of Ginkgo Bioworks, a synthetic biology company she helped establish in 2008 after completing her Ph.D. in biological engineering at MIT.
What does Ginkgo Bioworks do?
Ginkgo Bioworks engineers organisms for use across industries such as agriculture, pharmaceuticals, and specialty chemicals, using automated platforms to design and test genetic combinations at scale.
When did Ginkgo Bioworks go public?
Ginkgo Bioworks became a publicly traded company in 2021 through a merger with a special purpose acquisition company (SPAC).
Why is Reshma Shetty considered an important figure in biotech?
She represents one of the few women who co-founded a synthetic biology company from its academic research origins through to a public company listing, offering a model for scientists pursuing entrepreneurship in deep-tech fields.
Is Ginkgo Bioworks only focused on pharmaceuticals?
No. While pharmaceuticals are one application, Ginkgo Bioworks’ platform has been used across agriculture, industrial chemicals, and other sectors that rely on engineered organisms.
